Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Richard Huth who wrote (761)	5/8/1999 9:53:00 AM
From: yosi s	Respond to of 1386

Richard Thanks for the post. You are right in your assessment. I look for the company going forward, And not all forward movement generate cash in the near future. Thus if they put Le tobra application in. Progress is made though no cash. The same goes for partner in HU 211, I know I long it will take to complete the study. Look at phase 1,Phase 2 cohort 1, 2 and 3. Yet each phase gives us an answer. And a reason to assess where we stand. As long as information is + regarding HU 211. I think it is a worthwhile, long term investment. Once a breakthrough product hit the market it got a long life. See SKF, Glaxo, Astra Amgen etc. All propelled with a single product And all of them had their ups and down. Not to mention Amgen, A brewery saved them from going under.Look where they are now. So in summary. I am for the long haul. In the short term I like to see on going progress, and if short fall occur I check if they are do to growing problem or to major flaws.... Best Regards. As to estimates. I posted in the past What I thought revenues might be..(A complete guess on my part.)

To: Richard Huth who wrote (761)	5/9/1999 9:18:00 PM
From: arnie h	Read Replies (1) \| Respond to of 1386

Richard: You have a realistic perspective on PARS. Sales haven't come anyplace close to what company projections were. I hope we'll see some encouragement in the numbers but doubt it or the stock price wouldn't be so low nor would there be 1 million shares being sold short. Short sellers have always been on the money in PARS. HU 211 is a nice research program but until there is some tangible sign of endorsement by a partner, it remains that regardless of the optimism shown on the thread. We'll hope for the best but PARS shows little sign of being less than a long term, speculative investment much as are a large number of other small biotech companies. Arnie